Maternal serum screening for Down syndrome involves biochemical tests such as alpha-fetoprotein ( FP), human chorionic gonadotrophin (hCG) and unconjugated oestriol (uE 3 ), either alone or in combination, that have variable detection and false-positive rates. Choosing a screening protocol requires
LETTER TO THE EDITOR. SIMILARITIES IN WOMEN'S DECISION-MAKING IN THE U.S. AND U.K. DURING PRENATAL SCREENING FOR DOWN'S SYNDROME
โ Scribed by J. E. HADDOW; G. E. PALOMAKI
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 118 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0197-3851
No coin nor oath required. For personal study only.
โฆ Synopsis
Similarities in women's decison-making in the U.S. and U.K. during prenatal screening for Down's syndrome Data published from prenatal screening trials for Down's syndrome in the U.S. and U.K. allow a comparison to be made about patterns of decisionmaking among screen-positive women in the two countries, particularly regarding two critical decisions: whether to undergo amniocentesis and whether to terminate affected pregnancies. Summary data from an analysis of multiple marker screening studies (Palomaki et al., 1996a) allow amniocentesis acceptance rates to be computed for both the U.S. (an average of 79 per cent in six studies, range 68-92 per cent) and the U.K.
๐ SIMILAR VOLUMES